Teprotumumab

Introduction: What is Teprotumumab?

Teprotumumab is a monoclonal antibody medication primarily used to treat thyroid eye disease (TED), a condition often associated with Graves' disease. TED leads to inflammation and swelling of the eye muscles and surrounding tissues, causing symptoms such as bulging eyes, discomfort, and vision problems. Teprotumumab works by targeting and inhibiting the activity of insulin like growth factor-1 receptor (IGF-1R), which plays a significant role in the pathogenesis of TED.

Uses of Teprotumumab

Teprotumumab is approved for the treatment of thyroid eye disease in adults. It is specifically indicated for patients with moderate to severe TED who are experiencing significant symptoms. The medication has been shown to:

• Reduce proptosis (bulging of the eyes)
• Improve eye movement
• Alleviate other symptoms associated with the disease

How Does It Work?

Teprotumumab functions by blocking the IGF1R, which is involved in the inflammatory processes that lead to the symptoms of TED. By inhibiting this receptor, Teprotumumab reduces inflammation and the production of glycosaminoglycans, which contribute to the swelling of the eye muscles and surrounding tissues. In simpler terms, it helps calm down the overactive immune response that causes the eyes to bulge and become uncomfortable.

Dosage and Administration

Teprotumumab is administered via intravenous (IV) infusion. The standard dosing regimen for adults typically starts with a loading dose of 10 mg/kg, followed by 20 mg/kg every 3 weeks for a total of 8 infusions. The exact dosage may vary based on individual patient needs and the physician's recommendations. It is not approved for pediatric use, and its safety and efficacy in children have not been established.

Side Effects of Teprotumumab

Common side effects of Teprotumumab may include:

• Nausea
• Fatigue
• Diarrhea
• Hair loss
• Muscle spasms
• Dry skin
• Altered taste
• Elevated blood sugar levels (hyperglycemia)

Serious side effects can occur, such as:

• Infusion-related reactions (e.g., fever, chills, rash)
• Changes in vision
• Hearing problems
• Worsening diarrhea
• Inflammatory bowel disease exacerbation

Patients should report any unusual or severe side effects to their healthcare provider immediately.

Drug Interactions

Teprotumumab has no major CYP450 interactions. However, it may exacerbate hyperglycemia, particularly with medications affecting glucose control (e.g., insulin, oral antidiabetics). Inform your healthcare provider about all the medications, supplements, and herbal products you are taking.

Benefits of Teprotumumab

The clinical advantages of Teprotumumab include:

• Significant reduction in proptosis and improvement in eye symptoms.
• Potential to improve quality of life for patients suffering from TED.
• A targeted approach that may have fewer side effects compared to traditional therapies like corticosteroids.

Contraindications of Teprotumumab

Teprotumumab should be avoided in certain populations, including:

• Individuals with a history of severe allergic reactions (hypersensitivity) to Teprotumumab or any of its components.
• Pregnant women (pregnancy category not assigned; animal data show fetal harm).
• Breastfeeding due to potential excretion in milk.
• Patients with active infections or those who are immunocompromised should use caution.

Precautions and Warnings

Before starting Teprotumumab, patients should undergo a thorough medical evaluation. Important precautions include:

• Monitoring blood sugar levels, especially in patients with diabetes.
• Regular eye examinations to assess any changes in vision.
• Monitor for diarrhea and gastrointestinal symptoms; discontinue if severe.
• Assess baseline hearing via audiometry due to risk of hearing impairment.
• Inform healthcare providers about any preexisting conditions, particularly autoimmune disorders.

FAQs

1. What is Teprotumumab used for? Teprotumumab is used to treat thyroid eye disease, particularly in patients with moderate to severe symptoms.
2. How is Teprotumumab administered? It is given as an intravenous infusion, typically every three weeks for a total of eight doses.
3. What are the common side effects? Common side effects include nausea, fatigue, diarrhea, and hair loss.
4. Can I take Teprotumumab if I am pregnant? No, Teprotumumab is not recommended for pregnant or breastfeeding women.
5. How does Teprotumumab work? It blocks the IGF1 receptor, reducing inflammation and swelling in the eyes.
6. Are there any serious side effects? Yes, serious side effects can include infusion reactions and changes in vision.
7. Can Teprotumumab interact with other medications? Yes, it may interact with diabetes medications and corticosteroids.
8. How long does it take to see results? Improvements in proptosis seen as early as week 3 in trials, with full response by week 12-24 of starting treatment.
9. Is Teprotumumab safe for children? Its safety and efficacy in children have not been established, so it is not approved for pediatric use.
10. What should I do if I miss a dose? Contact your healthcare provider for guidance on rescheduling your infusion.

Brand Names

Teprotumumab is marketed under the brand name Tepezza (teprotumumab-trbw).

Conclusion

Teprotumumab represents a significant advancement in the treatment of thyroid eye disease, offering patients a targeted therapy that can alleviate symptoms and improve quality of life. With its unique mechanism of action and clinical benefits, it has become an essential option for managing this challenging condition. As with any medication, it is crucial to discuss potential risks and benefits with a healthcare provider to ensure safe and effective treatment.